Compare Alphabet Inc Class A (GOOGL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs BIO-TECHNE Corp — how do they compare? Alphabet Inc Class A trades at $350.67 (market cap $4.24T), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Alphabet Inc Class A is far larger — about 373.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and BIO-TECHNE Corp for 63 Days on average.
| GOOGL | TECH | |
|---|---|---|
Market Cap | $4.24T | $11.36B |
Volume | 23,392,850 | 5,390,331 |
Sector | Media | Health |
52-Week High | $402.62 | $72.61 |
52-Week Low | $236.59 | $43.31 |
Typical Hold Time | 85 Days | 63 Days |
Enterprise Value | $4.13T | $11.39B |
Dividend Yield | 0.25% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $350.50, up 0.81% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a 32.8% net income margin in 2025 and projected revenue growth to $445.9B in 2026. Analyst consensus is overwhelmingly positive, with an 86.75% buy rating and a $431.83 price target. Recent news highlights AI-driven growth opportunities and strategic partnerships.
The outlook for GOOGL remains favorable due to strong financial performance, AI integration, and analyst optimism. Key risks include regulatory scrutiny and market volatility. With solid cash flow and expanding profitability, the stock presents a compelling opportunity for growth-oriented investors, though attention to competitive and macroeconomic factors is advised.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
